Voyager Therapeutics (VYGR) Q3 2024 earnings summary

Executive summary

• Advanced pipeline with four wholly owned and 14 partnered programs, including progress in anti-Tau antibody and Tau silencing gene therapy for Alzheimer's, ALS, Parkinson's, and other CNS disorders.

• Completed enrollment and dosing in the VY7523 anti-Tau antibody Phase 1a trial for Alzheimer's, with top-line safety and PK data expected in H1 2025.

• Strong partnerships expanded, including a fifth TRACER capsid program with Novartis and a third development candidate with Neurocrine, triggering $18M in milestone and upfront payments.

• IND filings for three CNS gene therapies (ALS, GBA1 Parkinson's, Friedreich's ataxia) on track for 2025.

• Cash position of $345.4 million at Q3 2024 end, not including $18M in recent milestone payments, supporting operations into 2027.

Financial highlights

• Collaboration revenue rose to $24.6M in Q3 2024 from $4.6M in Q3 2023, driven by Novartis and Neurocrine agreements.

• Net loss narrowed to $9.0M in Q3 2024 from $25.9M in Q3 2023, mainly due to higher collaboration revenue.

• R&D expenses increased to $30.2M in Q3 2024, reflecting pipeline expansion and facility costs.

• Cash, cash equivalents, and marketable securities totaled $345.4M as of September 30, 2024, excluding $18M received in October.

• $15M from Novartis and $3M from Neurocrine to be booked in Q4 2024.

Outlook and guidance

• Cash position and expected collaboration reimbursements projected to fund operations and capital expenditures into 2027.

• Top-line safety and PK data from the VY7523 SAD trial expected in H1 2025; MAD trial in early Alzheimer's patients to start next year.

• Multiple clinical and regulatory milestones anticipated through 2026, including IND filings and data readouts for key programs.

• Initial Tau PET imaging data from the MAD trial anticipated in H2 2026.

• Tau silencing gene therapy program on track for U.S. IND and Health Canada CTA filings in 2026.